Stocktoria
Silence Therapeutics plc SLN
Silence Therapeutics plc (SLN) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $559,000 at a -15851.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.799 |
| Retained earnings / assets | -4.28 |
| EBIT / assets | -0.693 |
| Equity / liabilities | 0.901 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SLN | Silence Therapeutics plc | 1/9 | -12.42 | — | -98.7% |
| VYNE | VYNE Therapeutics Inc. | 2/9 | — | — | — |
| QUCY | Quantum Cyber N.V. | 3/9 | — | — | — |
| ELAB | PMGC Holdings Inc. | 2/9 | — | — | — |
| VCNX | VACCINEX, INC. | 3/9 | — | — | — |
| MREO | Mereo BioPharma Group plc | 3/9 | — | — | — |
| BTAI | BioXcel Therapeutics, Inc. | 2/9 | — | — | — |
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
FAQ
Is SLN financially healthy?
Silence Therapeutics plc's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SLN pay a dividend?
No, Silence Therapeutics plc does not currently pay a dividend.
How profitable is SLN?
In FY2025, Silence Therapeutics plc had a net margin of -15851.9% and a return on equity of -142.2%.
What is the analyst price target for SLN?
The average Wall-Street price target for Silence Therapeutics plc is $29.17, about 114.8% above the recent price, from 6 analysts (consensus: buy).
Is SLN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Silence Therapeutics plc: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.